Sanofi Fair Value
Sanofi (SANOFI) average fair value is ₹700.22 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹3087.4 (-77.32%), fair value range ₹147.49–₹1091.22. Browse SANOFI balance sheet details for revenue, profit, balance sheet and cash flow data.
Fair Value Analysis Export
SANOFI Fair Value vs Current Price — Valuation Summary
SANOFI average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. Read SANOFI dividend growth for the complete payout history and dividend yield track record.
P/E Based Valuation
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
SANOFI Fair Value Analysis — Data Sources & Coverage
Sanofi financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit SANOFI stock price BSE.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
SANOFI vs Healthcare Sector Peers — P/E, P/B & Market Cap
Sanofi P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.